Dr Laurent Le Cam
Inserm Research Director and Deputy director of Institut de Recherche en Cancérologie de Montpellier (IRCM - Inserm U1194) and Group Leader of the Molecular oncogenesis team, will be presenting his work:
The p53 pathway and metabolism: implications in development, aging and cancer
Abstract:
Mutation of the TP53 gene is the most frequent genetic alteration in human cancers. Tumor suppressive functions of p53 have been linked to its ability to control cell division, cell death and cellular senescence. However growing evidence indicates that the metabolic functions of p53 play important roles in cancer progression. Our team has been studying the metabolic functions of the p53 pathway for many years and highlighted previously unknown functions of several key components of this molecular cascade in pyruvate, amino-acid, and nucleotide metabolism. Beyond cancer development, I will illustrate how deregulation of these metabolic networks impacts on normal physiological responses in the liver and leads to inborn metabolic disorders.
Relevant publications:
- Arena et al. Mitochondrial MDM2 regulates respiratory complex I activity independently of p53. Mol Cell 2018
- Cissé et al. Targeting MDM2-dependent serine metabolism as a new therapeutic strategy for liposarcoma. Sci Trans Med 2020
- Lacroix et al. The multifunctional protein E4F1 links p53 to lipid metabolism in adipocytes. Nat Comms 2021
- Di Michele et al. E4F1 coordinates pyruvate metabolism and the activity of the Elongator Complex to ensure protein translation fidelity. BioRxiv
